Phaseline

Companies › Molecular Partners

Molecular Partners: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[212Pb]Pb-MP0712
DLL3-targeting radioligand therapy (alpha particle emitter)
DLL3Phase 1Large Cell Neuroendocrine CarcinomaSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07278479[212Pb]Pb-MP0712Phase 1Large Cell Neuroendocrine CarcinomaOncologySep 2028

From the company's SEC filings

Cash of 83m CHF on 2025-12-31; operating cash outflow about 51m CHF a year; runway about 19 months at that burn, to Aug 2027

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DLL3 (1)

Companies with the same targets

Novartis Boehringer Ingelheim Daiichi Sankyo Amgen AbbVie IDEAYA Biosciences Beijing Biotech Phanes Therapeutics Abdera Therapeutics Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.